Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 8Myeloid 7Classical hematology 4Tumor-Agnostic 3Other solid neoplasm 3Lymphoid 3Gastrointestinal 3Head & Neck 2Thoracic 1Plasma cell 1Other neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
ON 01910 × Tumor-Agnostic × Clear all
NCT01165905 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Traws Pharma, Inc.

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT01538537 2017-06-23

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasms

NCT01538563 2017-06-23

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Traws Pharma, Inc.

Phase 1 Completed
42 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡